5-Amino-1MQ Benefits: What the Research Actually Shows

The honest summary of the table: a consistent mouse and cell story from essentially one research group, a human observation about the enzyme it targets, and no study of the compound in a person.

5-Amino-1MQ is short for 5-amino-1-methylquinolinium, a small synthetic molecule built on a quinolinium ring, with no amino acids in it; it is not a peptide (is 5-Amino-1MQ a peptide explains why). It came from a medicinal chemistry program at the University of Texas Medical Branch in Galveston, led by Stanley Watowich. It blocks the enzyme nicotinamide N-methyltransferase (NNMT). NNMT takes nicotinamide, the form of vitamin B3 cells recycle into NAD+, and attaches a methyl group from S-adenosylmethionine (SAM), the cell's main methyl donor; the product is excreted rather than reused. Blocking the enzyme is proposed to keep both the NAD+ precursor and SAM in the cell. It is not a hormone, not a GLP-1 medication, not a stimulant, and does not contain NAD+. Every benefit below hangs off that one enzyme.

The idea came from a 2014 paper in Nature from Barbara Kahn's laboratory at Beth Israel Deaconess and Harvard, which reported NNMT expression rising in the white fat and liver of obese and diabetic mice, and reported that knocking the enzyme down protected mice against diet-induced obesity. Knocking it down was reported to increase energy expenditure in fat cells, with SAM and NAD+ rising and two enzymes of polyamine metabolism being switched up. That study used a genetic technique, not 5-Amino-1MQ, so it describes the target rather than this molecule. The Galveston group set out to do the same thing with a drug, and a 2017 Journal of Medicinal Chemistry paper identified quinoliniums as the promising series.

What the research describes. The 2018 Biochemical Pharmacology study treated diet-induced obese mice with a potent NNMT inhibitor and reported reduced body weight, reduced white fat mass and smaller fat cells, with total food intake unchanged. The 2024 paper in Diabetes, Obesity and Metabolism dosed the compound once daily for 28 days in diet-induced obese mice and reported dose-dependent limiting of body weight and fat mass gain.

Evidence type. Animal.

What it means. These are the findings most often quoted for 5-Amino-1MQ, and they are mouse findings. Mouse body-composition results frequently do not translate to people, and this compound has not been tested for translation. There is no human trial showing weight loss or fat loss from 5-Amino-1MQ. If losing weight is the actual goal, the best peptides for weight loss sets out the medications with human evidence for it.

What the research describes. The 2018 Biochemical Pharmacology paper measured what NNMT inhibitors did inside cultured fat cells: lower 1-methylnicotinamide, the enzyme's product, and higher intracellular NAD+ and SAM.

Evidence type. Cell.

What it means. This is the origin of the "raises NAD+" description. It is a cell-culture measurement and has not been reproduced in human tissue; whether 5-Amino-1MQ changes NAD+ in a person has never been measured. It does not contain NAD+ and does not supply it. If NAD+ itself is the interest, NAD+ injection supplies the molecule directly, and NAD+ benefits covers its own evidence.

What the research describes. The same 2018 cell work reported suppressed lipogenesis, the building of new fat within the cell, in cultured fat cells treated with NNMT inhibitors.

Evidence type. Cell.

Strength. A laboratory measurement in a dish. It is a plausible link between the enzyme and the mouse results, and the furthest of these benefits from anything a person would notice.

What the research describes. The 2024 Diabetes, Obesity and Metabolism paper reported improved oral glucose tolerance and insulin sensitivity and suppressed hyperinsulinaemia, meaning less excess insulin in the blood, in diet-induced obese mice treated for 28 days.

The human angle. A 2015 study in Diabetologia measured NNMT in fat tissue from 199 people undergoing abdominal surgery and reported it roughly twofold higher in people with type 2 diabetes, with plasma 1-methylnicotinamide tracking tissue NNMT and both correlating with insulin resistance. Exercise and bariatric surgery were associated with lower NNMT expression. Nobody in that study was given 5-Amino-1MQ.

Evidence type. Animal, plus human observation of the target enzyme.

Strength. The best argument for studying 5-Amino-1MQ in people, and still not evidence that it does anything in them. It is not a treatment for diabetes. If you take anything that lowers blood sugar, it belongs on your intake.

What the research describes. The 2024 mouse paper reported less hepatic steatosis (fat in the liver) and less macrophage infiltration on liver histology, and normalisation of the liver enzymes ALT and AST and of ketone bodies, in treated obese mice.

Evidence type. Animal.

What it means. One mouse study. It is also part of the safety picture: in those mice, liver enzymes moved toward normal rather than rising. It is not evidence of any effect on the human liver, and it is not a treatment for liver disease.

What the research describes. The 2018 Biochemical Pharmacology study reported lower plasma total cholesterol in treated diet-induced obese mice.

Evidence type. Animal.

Strength. A secondary finding in one mouse study. Nothing in people.

What the research describes. A 2022 study in Scientific Reports combined the inhibitor with a switch from a high-fat Western diet to a low-fat diet in diet-induced obese mice, and reported that the combination normalised adiposity and weight to those of lean animals faster than the diet switch alone, with a distinct gut microbiome pattern in treated mice.

Evidence type. Animal.

What it means. A small mechanistic study, and it says nothing about a person who has not changed their diet. It is one reason prescribers describe 5-Amino-1MQ as an adjunct to diet and activity, not a replacement.

What the research describes. A 2019 paper in Biochemical Pharmacology from the Galveston group described NNMT as overexpressed in aged skeletal muscle and linked it to impaired NAD+ salvage and senescence of muscle stem cells. In 24-month-old mice given an acute muscle injury, treatment was reported to raise muscle stem cell activity and support larger regenerated muscle fibres. A 2024 paper in Scientific Reports treated mice from 22 to 24 months of age with the inhibitor, intensive exercise, or both, and reported greater grip strength in treated sedentary mice than in sedentary controls, with an additive effect when combined with exercise.

Evidence type. Animal.

What it means. The mice were chosen because they recapitulate features of human sarcopenia, age-related muscle loss. That is a rationale for studying it in older people; it is not a study in people, and 5-Amino-1MQ is not a treatment for muscle loss.

What the research describes. The 2018 mouse work reported total food intake unchanged in treated animals.

What it means. The mechanism described is inside fat cells, not in the appetite centers of the brain. 5-Amino-1MQ is not a GLP-1 medication and should not be expected to reduce hunger. That is a difference in mechanism, and it is why some physicians prescribe it alongside a GLP-1 rather than instead of one; no human study has tested that combination. See what peptides can you take with tirzepatide.

• That 5-Amino-1MQ does anything in a human being. Mouse body-composition findings frequently do not translate, and this compound has not been tested for translation.
• An effect size. No human trial has measured one.
• A timeline in humans. The 28-day mouse study is the closest thing to a duration reference.
• That it raises NAD+ in people.
• Long-term safety in humans. There is no human safety database of any size.
• An interaction profile. NNMT also methylates foreign compounds, which is a theoretical reason for care, and nothing more is known.
• Efficacy for any condition as an FDA-approved treatment. It is not approved for anything.

Physicians have prescribed compounded 5-Amino-1MQ for several years, and that experience is real, but it is uncontrolled. The honest framing is "described in mouse and cell research and used clinically," not "shown to work in people." Anyone describing human results is describing something that does not exist.

Where it stands with the FDA

5-Amino-1MQ is not an FDA-approved drug, is not a component of one, and has no USP monograph. It is not on the 503A bulks list, and it does not appear in Category 1, 2 or 3 of the FDA's nominated-substances list as updated 14 May 2026. The FDA has never published a safety-risk finding about it, and it was not among the substances the Pharmacy Compounding Advisory Committee reviewed in July 2026. It has simply not been through the FDA's evaluation process. It remains a compounded, prescription-only medication, and compounded medications are not FDA approved. See are peptides FDA approved.

These are the three metabolic options people most often compare, and none has a randomised human trial.

No study has compared any two of them. The useful difference is where each acts, not which is "strongest". The full side-by-side is in MOTS-c vs SLU-PP-332 vs 5-Amino-1MQ, and the MOTS-c evidence is in MOTS-c benefits.

There is no human safety database and no established interaction list, which is why the intake asks for every medication and supplement you take. 5-Amino-1MQ is not used in pregnancy or breastfeeding. Tested athletes should check the current prohibited list for their sport. The full list is in 5-Amino-1MQ side effects.

Every price is all-in, covering medication, physician review, refill management and shipping, with no separate membership fee. Pepti is cash-pay and does not bill insurance. Pepti supplies 5-Amino-1MQ as an injection only, not as a capsule, pen or nasal spray. Vials are multi-dose solutions shipped ready to use, refrigerated with ice packs, with sterile syringes and alcohol prep pads. Refills run every 28 days, one vial per fill. Your physician sets your directions after reviewing your intake, and they are printed on the vial. The unit and milligram arithmetic is in 5-Amino-1MQ dosage.

5-Amino-1MQ cannot be bought legitimately without a prescription. Sites selling it "for research use only" are not accountable for identity, purity, sterility or concentration. The prescription route:

1. Complete a free online intake covering your history, medications and what you want help with.
2. A physician licensed in your state reviews it, usually within 24 hours.
3. If it is appropriate, a PCAB-accredited, FDA-registered US 503A compounding pharmacy prepares it to that prescription. Lot test results are published at /quality/lab-results.
4. It ships refrigerated with your directions printed on the vial.
5. Your physician stays reachable for questions and side effects.

Pepti prescribes 5-Amino-1MQ in every state except Oklahoma, plus DC The step-by-step page is how to get 5-Amino-1MQ prescribed online.